Revista Brasileira de Hematologia e Hemoterapia Revista Brasileira de Hematologia e Hemoterapia
Rev Bras Hematol Hemoter 2017;39:93-4 DOI: 10.1016/j.bjhh.2017.01.002
Erratum
Erratum to “Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia” [Rev Bras Hematol Hemoter. 2016;38(4):346–357]
Celso Arrais Rodriguesa,b,, , Matheus Vescovi Gonçalvesa,c, Maura Rosane Valério Ikomad, Irene Lorand-Metzee, André Domingues Pereirab, Danielle Leão Cordeiro de Fariasf, Maria de Lourdes Lopes Ferrari Chauffaillea,c, Rony Schaffelg, Eduardo Flávio Oliveira Ribeiroh, Talita Silveira da Rochai,j, Valeria Buccherik, Yuri Vasconcelosl, Vera Lúcia de Piratininga Figueiredom, Carlos Sérgio Chiattonej,n, Mihoko Yamamotoa, on behalf of the Brazilian Group of Chronic Lymphocytic Leukemia
a Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
b Hospital Sírio Libanês, São Paulo, SP, Brazil
c Fleury Medicina e Saúde, São Paulo, SP, Brazil
d Hospital Amaral Carvalho, Jaú, SP, Brazil
e Universidade Estadual de Campinas (UNICAMP), São Paulo, SP, Brazil
f Universidade Federal de Goiás (UFG), Goiânia, GO, Brazil
g Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
h Hospital Santa Lúcia, Brasília, DF, Brazil
i A.C Camargo Cancer Center, São Paulo, SP, Brazil
j Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil
k Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil
l Instituto Goiano de Oncologia e Hematologia (INGOH), Goiânia, GO, Brazil
m Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, SP, Brazil
n Hospital Samaritano, São Paulo, SP, Brazil

In the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction:

2) Relapsed first-line treatment:

  • a)

    Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)

  • b)

    Progress within 24 months:

    • -

      ‘Go-go’ patients: ibrutinib

      • Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab

    • -

      ‘Slow-go’ patients: ibrutinib

      • Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite

Copyright © 2016. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Rev Bras Hematol Hemoter 2017;39:93-4 DOI: 10.1016/j.bjhh.2017.01.002